Anticholinergic burden in older adults with hyperpolypharmacy: a comparison of the drug burden index, anticholinergic cognitive burden, and duran scales in primary care

Abstract To evaluate anticholinergic burden in older adults (≥ 65 years) with hyperpolypharmacy (≥ 10 medications) in primary care using the Drug Burden Index (DBI), and to compare the results with those obtained using the Anticholinergic Cognitive Burden (ACB) scale and Duran’s scale. Additionally, factors associated with increased anticholinergic burden were explored. A multicenter cross-sectional study was conducted including 6,550 patients aged ≥ 65 years with hyperpolypharmacy in primary care settings. Sociodemographic, clinical, functional, and pharmacotherapeutic variables were obtained from electronic health records. Anticholinergic burden was assessed using the DBI, ACB, and Duran’s scales. Differences in burden according to patient characteristics were analyzed. Overall, 83.3% of patients were prescribed at least one medication with anticholinergic activity. According to the DBI, 50.2% of patients were classified as having a high anticholinergic burden, 44.2% as moderate burden, and 5.6% as having no risk. In contrast, the ACB scale classified 24.8% of patients as high risk, while Duran’s scale identified 27.2% as high risk. Mean DBI values were significantly higher among women, patients with dementia, individuals with greater cognitive and functional impairment, and those receiving ≥ 15 medications. Lorazepam and tramadol were the most frequently prescribed medications contributing to anticholinergic burden. Anticholinergic burden in older adults with hyperpolypharmacy varies substantially depending on the assessment tool used. The DBI identified a considerably higher burden than the ACB and Duran’s scales, reflecting important methodological differences among instruments. Systematic assessment of anticholinergic burden and regular medication review may help optimize pharmacotherapy and improve medication safety in this vulnerable population.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-10-03
DOI
https://doi.org/10.1038/s41598-026-73968-9
Primary Topic
Pharmaceutical Practices and Patient Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Anticholinergic burden in older adults with hyperpolypharmacy: a comparison of the drug burden index, anticholinergic cognitive burden, and duran scales in primary care

Antonio J. Braza, Montserrat Viñas-Bastart, Neus Parellada Esquius, Gemma Rodríguez Palomar et al.
Scientific Reports
Pharmaceutical Practices and Patient Outcomes
article

Anticholinergic burden in older adults with hyperpolypharmacy: a comparison of the drug burden index, anticholinergic cognitive burden, and duran scales in primary care

Antonio J. Braza, Montserrat Viñas-Bastart, Neus Parellada Esquius, Gemma Rodríguez Palomar, Pilar Modamio, María José Sarria Arroyo
article en

Abstract

Abstract To evaluate anticholinergic burden in older adults (≥ 65 years) with hyperpolypharmacy (≥ 10 medications) in primary care using the Drug Burden Index (DBI), and to compare the results with those obtained using the Anticholinergic Cognitive Burden (ACB) scale and Duran’s scale. Additionally, factors associated with increased anticholinergic burden were explored. A multicenter cross-sectional study was conducted including 6,550 patients aged ≥ 65 years with hyperpolypharmacy in primary care settings. Sociodemographic, clinical, functional, and pharmacotherapeutic variables were obtained from electronic health records. Anticholinergic burden was assessed using the DBI, ACB, and Duran’s scales. Differences in burden according to patient characteristics were analyzed. Overall, 83.3% of patients were prescribed at least one medication with anticholinergic activity. According to the DBI, 50.2% of patients were classified as having a high anticholinergic burden, 44.2% as moderate burden, and 5.6% as having no risk. In contrast, the ACB scale classified 24.8% of patients as high risk, while Duran’s scale identified 27.2% as high risk. Mean DBI values were significantly higher among women, patients with dementia, individuals with greater cognitive and functional impairment, and those receiving ≥ 15 medications. Lorazepam and tramadol were the most frequently prescribed medications contributing to anticholinergic burden. Anticholinergic burden in older adults with hyperpolypharmacy varies substantially depending on the assessment tool used. The DBI identified a considerably higher burden than the ACB and Duran’s scales, reflecting important methodological differences among instruments. Systematic assessment of anticholinergic burden and regular medication review may help optimize pharmacotherapy and improve medication safety in this vulnerable population.

Scientific Reports
Generalitat de Catalunya (ES), Departament de Salut (ES), Institut Català de la Salut (ES)
Openalex Percentile: Top 15%
Pharmaceutical Practices and Patient Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.